Drug file · From the Watchtower
Teclistamab: the briefings and the record
Every Prognyx briefing on teclistamab, newest first, and the dated events drawn from the sources those briefings cite. Rebuilt with each new briefing.
- Also known as
- TECVAYLI
- Target, as briefed
- BCMA x CD3 bispecific + GPRC5D x CD3 bispecific; trispecific antibody (DARZALEX-based); BCMA x CD3 bispecific antibody
- Companies named
- Johnson & Johnson
- Prognyx coverage
- 2 briefings, 19 September 2026 to 11 November 2026
Prognyx briefings on teclistamab
- relapsed/refractory multiple myeloma (second-line and beyond)J&J's TECVAYLI-TALVEY Phase 3 cuts myeloma progression risk as early as second line
The company's ASH 2026 release reports Phase 3 data for the TECVAYLI-TALVEY bispecific pair reducing progression risk in relapsed myeloma as early as second line, plus first results for ramantamig, a trispecific built on DARZALEX.
- relapsed/refractory multiple myeloma after one prior therapyCHMP backs J&J's teclistamab for earlier-line relapsed/refractory myeloma
The EMA's committee adopted a positive opinion on 17 September 2026 recommending TECVAYLI after just one prior therapy, per the EMA, J&J's release and OncLive, pushing the BCMA bispecific fight closer to second line.
Sourced timeline
Readouts, regulatory actions, filings, trial starts and deals that the Prognyx engine extracted from the documents cited in these briefings, newest first. Each links to its source and to the briefing that cited it. Press coverage is left out, and so is any event dated on its own briefing's day: the briefing above is the record for that day. A month without a day is a date the source gave only to the month.
- Regulatory actionEC approves TECVAYLI + daratumumab for R/R MMCompany release (GlobeNewswire) · cited in CHMP backs J&J's teclistamab for earlier-line relapsed/refracto…
- Regulatory actionFDA approves TECVAYLI + DARZALEX FASPRO as early as 2nd lineCompany release (PR Newswire) · cited in CHMP backs J&J's teclistamab for earlier-line relapsed/refracto…
- TerminationNCT06588660 (ST-067 + teclistamab) terminated, end of fundingClinicalTrials.gov · cited in J&J's TECVAYLI-TALVEY Phase 3 cuts myeloma progression risk as…
Registered trials on file
ClinicalTrials.gov records that the cited sources tie to teclistamab, each opening on the registry.
- NCT07791498 NCT07791498 (teclistamab in Waldenström's, Ph2)
- NCT07728188
- NCT07657312 Infliximab for CRS prophylaxis during teclistamab or talquetamab (Phase 2)
- NCT07518186 NCT07518186 (JNJ-79635322 vs teclistamab, Ph3)
- NCT07463807 Teclistamab + pomalidomide vs KPd (Phase 1/2)
- NCT07332507 NCT07332507 (teclistamab in plasmablastic lymphoma, Ph1)
- NCT06948084 NCT06948084 (daratumumab+teclistamab, Ph2)
- NCT06588660 ST-067 + teclistamab (Phase 1)
- NCT06465316
- NCT04557098
The Watchtower, by email
The next move on teclistamab, the day it happens.
The next readout, FDA/EMA action or deal on teclistamab reaches you by email the day we publish it. One email per briefing, nothing else.
Double opt-in. Never sold, no open tracking. Privacy.
Get a free sample competitive brief on one of your assets, sourced, sharp, no strings.
Request a sample brief → Or read how Prognyx runs continuous oncology competitive intelligence.
Prognyx briefings are built from public information and reflect Prognyx's analysis. They are not investment advice and do not promote any product or off-label use. Event titles are written by the Prognyx engine from the linked source; the source is the record.